Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference
June 13, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s Disease
April 20, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
Phase 2/3 Trial Planned in Agitation in Alzheimer’s DiseaseIND Submission Expected in 2016 NEW YORK, April 20, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
March 17, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
First Patient Enrolled in the STRIDE-1 Study Second Product Candidate Axsome Has Advanced into a Pivotal Trial NEW YORK, March 17, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc....
Axsome Therapeutics to Present at the 2016 BIO CEO & Investor Conference
February 01, 2016 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous...